Indeed, the combination of anti-KLRG1 with other inhibitors can improve the antitumor response in mice with melanoma, further reducing the metastatic potential of breast cancer and effectively preventing metastatic recurrence [23, 26]. Here, KLRG1 is linked to breast cancer.